Resistance to Second-Line Antiretroviral Therapy in HIV-infected Adults in Asia : The TASER Second-Line Study – TASER 2

The study will involve TAHOD participating sites that do and do not perform routine HIV VL and/or HIV genotype (GT) resistance testing. Study design will vary depending on whether a site performs routine HIV VL and/or GT testing.

TAHOD participating sites that do not perform routine HIV VL and/or HIV GT resistance testing (“testing sites”) will perform cross-sectional testing on eligible patients. TAHOD participating sites that do perform routine HIV VL and/or HIV GT resistance testing will collect existing HIV VL and/or HIV GT resistance data from eligible patients (“data sites”):

1. Cross-sectional assessment: Eligible patients without available HIV VL and/or GT resistance testing will have cross-sectional testing done for the purposes of the study.

2. Collection of existing data: Data from eligible patients with available HIV VL and/or GT resistance testing results will be contributed to the study/analysis.

Both types of participating study sites will also contribute HIV demographic, clinical, and laboratory data for all patients included.